Comparative Pharmacology
Head-to-head clinical analysis: ACTHAR GEL AUTOINJECTOR versus CORTROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTHAR GEL AUTOINJECTOR versus CORTROSYN.
ACTHAR GEL (AUTOINJECTOR) vs CORTROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTHAR Gel (repository corticotropin injection) acts primarily by stimulating the adrenal cortex to secrete corticosteroids (cortisol, corticosterone, and aldosterone), which exert anti-inflammatory, immunosuppressive, and antiproliferative effects. The exact mechanism in specific indications (e.g., infantile spasms) is not fully understood but may involve modulation of the hypothalamic-pituitary-adrenal axis and direct effects on the central nervous system.
Corticotropin (ACTH) stimulates the adrenal cortex to release cortisol, corticosterone, and aldosterone; used diagnostically to assess adrenal function.
Initial: 40-80 units intramuscularly or subcutaneously every 24-48 hours; maintenance: 20-40 units intramuscularly or subcutaneously every 48 hours. Titrate based on response.
For diagnostic testing of adrenal function: 250 mcg intramuscularly or intravenously as a single dose. For infants and children: 125 mcg intramuscularly or intravenously as a single dose.
None Documented
None Documented
The terminal half-life of exogenously administered ACTH is approximately 15 minutes; however, the duration of adrenal cortisol stimulation persists for 6-12 hours after IM administration due to prolonged absorption from the gel formulation.
Terminal half-life approximately 1.5 hours (dose-dependent: 1.1-2.2 h). Rapid clearance limits duration of action.
ACTH (corticotropin) is metabolized by tissue peptidases; renal excretion accounts for <5% of unchanged drug. Biliary/fecal elimination is negligible.
Primarily renal (90% as metabolites, 10% unchanged); negligible biliary/fecal.
Category C
Category C
Corticotropin
Corticotropin